WALNUT CREEK, Calif., and BEIJING, China, May 11, 2026
Dark Horse Consulting Group (DHCG) and KunTuo Medical Research and Development (Beijing) Co., Ltd. announced the signing of a strategic Memorandum of Understanding (MOU) aimed at accelerating cell and gene therapy (CGT) clinical development programs in China. The partnership is designed to provide biotechnology and biopharmaceutical developers with an integrated pathway for conducting clinical trials in one of the world’s fastest-growing advanced therapy markets. The collaboration combines DHCG’s global regulatory and biotherapeutics consulting expertise with KunTuo’s extensive local clinical research infrastructure and operational capabilities across China.
The agreement reflects growing international demand for streamlined access to China’s rapidly expanding clinical development ecosystem, particularly for innovative therapies such as cell therapies, gene therapies, regenerative medicines, and advanced biologics. Industry experts continue to identify China as a strategically important market for next-generation therapeutic development due to its large patient populations, expanding regulatory modernization, and growing investment in advanced biotechnology infrastructure.
Integrated Clinical Development Platform Targets Global Biotech Expansion
Under the collaboration, DHCG and KunTuo will provide biotechnology companies with a comprehensive framework supporting programs from global regulatory strategy through local clinical execution in China. The initiative is expected to simplify complex cross-border clinical development processes by combining regulatory planning, clinical trial management, quality and compliance consulting, supply chain coordination, and commercialization support under a unified operational structure.
KunTuo, established by IQVIA specifically for the Chinese market, has delivered more than 1,000 clinical research services since its founding in 2011 and maintains a large operational network covering nearly 500 institutions and departments across China. The organization has developed a dedicated cell and gene therapy clinical team focused on managing advanced therapy programs at leading Chinese research institutions. DHCG contributes specialized expertise in global regulatory affairs, Chemistry, Manufacturing and Controls (CMC), clinical design strategy, quality systems, and compliance requirements necessary for international regulatory submissions involving data generated in China.
Advertisement
The companies stated that the collaboration directly addresses persistent industry challenges involving differences between international regulatory expectations and local clinical trial execution standards. Sponsors developing advanced therapies often encounter delays and operational complexity when attempting to align Chinese clinical programs with U.S. FDA and international regulatory requirements. The partnership aims to reduce those barriers while enabling sponsors to move programs into clinical development more efficiently and with greater confidence.
Cell and Gene Therapy Market Growth Drives Strategic Collaboration
The global cell and gene therapy sector continues to experience rapid expansion as biotechnology companies increasingly pursue innovative treatments targeting oncology, rare diseases, autoimmune conditions, and regenerative medicine applications. China has emerged as one of the most active regions for advanced therapy clinical research, attracting growing attention from global biotechnology developers seeking accelerated patient recruitment, manufacturing capabilities, and access to expanding healthcare infrastructure.
Anthony Davies, Ph.D., Founder and CEO of Dark Horse Consulting Group, stated that the collaboration represents a significant expansion of the company’s integrated service offerings for clients advancing programs within China. He emphasized that combining KunTuo’s operational expertise with DHCG’s global strategic consulting capabilities creates a differentiated solution spanning every stage of therapeutic development.
KunTuo General Manager Linda Wang highlighted the increasing importance of cell and gene therapies as one of the most promising frontiers in modern biopharmaceutical innovation. According to Wang, the partnership will provide developers worldwide with a “one-stop solution” covering regulatory strategy, drug development, and local clinical execution designed to accelerate patient access to innovative therapies.
Global Biopharma Partnerships Continue Expanding in China
The collaboration becomes effective immediately, with both companies expecting to initiate joint client engagements in the near future. Analysts note that strategic alliances between global consulting organizations and China-based clinical research providers are becoming increasingly common as biotechnology companies seek efficient pathways for multinational development programs.
As regulatory agencies worldwide continue modernizing frameworks for advanced therapies, partnerships focused on harmonizing global development strategies with local operational expertise are expected to play a growing role in accelerating commercialization timelines for cell and gene therapies. The DHCG-KunTuo agreement further highlights the increasing globalization of clinical development activities and the rising importance of China within the future biopharmaceutical innovation landscape.
Source: Dark Horse Consulting Group press release
